Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients

Experimental Hematology

Volumn 41, Issue 2, 2013, Pages 167-171

  Oster, Howard S ^a   Prutchi Sagiv, Sara ^a   Halutz, Ora ^b   Shabtai, Esther ^a   Hoffman, Michael ^a   Neumann, Drorit ^a   Mittelman, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; INFLUENZA VACCINE; RECOMBINANT ERYTHROPOIETIN;

AGE DISTRIBUTION; AGED; ANEMIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; HEPATITIS B; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLUENZA VACCINATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SEASONAL INFLUENZA; TREATMENT OUTCOME;

AGED; ANEMIA; ANTIBODIES, VIRAL; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS; INFLUENZA VACCINES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECOMBINANT PROTEINS; VACCINATION;

EID: 84873506161     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.011     Document Type: Article

References (32)

1. Erslev A.J. Erythropoietin. N Engl J Med 1991, 324:1339-1344.
2. Eschbach J.W., Kelly M.R., Haley N.R., Abels R.I., Adamson J.W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989, 321:158-163.
3. Aapro M., Spivak J.L. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009, 14(Suppl 1):6-15.
4. Oster H.S., Hoffman M., Prutchi-Sagiv S., Katz O., Neumann D., Mittelman M. Erythropoietin in clinical practice: current use, effect on survival, and future directions. Isr Med Assoc J 2006, 8:703-706.
5. Osterborg A., Brandberg Y., Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005, 129:206-209.
6. Spivak J.L. Recombinant human erythropoietin and the anemia of cancer. Blood 1994, 84:997-1004.
7. Mittelman M., Zeidman A., Fradin Z., Magazanik A., Lewinski U.H., Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997, 98:204-210.
8. Mittelman M. The myelodysplastic syndromes-1990. Isr J Med Sci 1990, 26:468-478.
9. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000, 97:10526-10531.
10. Kaptanoglu E., Solaroglu I., Okutan O., Surucu H.S., Akbiyik F., Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004, 27:113-120.
11. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003, 112:999-1007.
12. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004, 18:1031-1033.
13. Anagnostou A., Liu Z., Steiner M., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994, 91:3974-3978.
14. Buemi M., Cavallaro E., Floccari F., et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003, 62:228-236.
15. Prutchi-Sagiv S., Mittelman M., Neumann D. A hematopoietic hormone with emerging diverse activities. The Handbook of Biologically Active Peptides 2006, 1411-1418. Elsevier, San Diego. A.J. Kastin (Ed.).
16. Mittelman M., Zeidman A., Kanter P., et al. Erythropoietin has an anti-myeloma effect-a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 2004, 72:155-165.
17. Mittelman M., Neumann D., Peled A., Kanter P., Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001, 98:5181-5186.
18. Prutchi-Sagiv S., Golishevsky N., Katz O., et al. T-cell abnormalities in patients with myelodysplastic syndromes: Improved immunological functions in patients treated with recombinant erythropoietin. Blood 2006, 108:756a.
19. Prutchi-Sagiv S., Golishevsky N., Oster H.S., et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?. Br J Haematol 2006, 135:660-672.
20. Katz O., Gil L., Lifshitz L., et al. Erythropoietin enhances immune responses in mice. Eur J Immunol 2007, 37:1584-1593.
21. Hassan K., Shternberg L., Alhaj M., et al. The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease. Ren Fail 2003, 25:471-478.
22. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
23. Tosh P.K., Jacobson R.M., Poland G.A. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010, 85:257-273.
24. Lemaitre M., Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis 2010, 10:162.
25. Mazza J.J., Yale S.H., Arrowood J.R., et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005, 3:214-220.
26. Pollyea D.A., Brown J.M., Horning S.J. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010, 28:2481-2490.
27. Stadtmauer E.A., Vogl D.T., Luning Prak E., et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: Results of a randomized clinical trial. Blood 2011, 117:63-71.
28. Siegrist C.A. Vaccine immunology. Vaccines 2008, 17-36. Elsevier, Philadelphia. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
29. Bucasas K.L., Franco L.M., Shaw C.A., et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011, 203:921-929.
30. Lifshitz L., Prutchi-Sagiv S., Avneon M., Gassmann M., Mittelman M., Neumann D. Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol 2009, 46:713-721.
31. Prutchi Sagiv S., Lifshitz L., Orkin R., Mittelman M., Neumann D. Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?. Exp Hematol 2008, 36:1682-1690.
32. Rocchetta F., Solini S., Mister M., et al. Erythropoietin enhances immunostimulatory properties of immature dendritic cells. Clin Exp Immunol 2011, 165:202-210.